Skip to main content
. 2024 Mar 18;71:102553. doi: 10.1016/j.eclinm.2024.102553

Fig. 2.

Fig. 2

Fig. 2

EPICOVIDEHA 2020–2022 patients: COVID-19 severity prevalence and mortality rate, overall mortality rate, mortality per malignancy status at COVID-19 onset, and mortality per reason for mortality. A) 2020–2022 COVID-19 severity prevalence. B) 2020–2022 mortality rate overall. C) 2020–2022 mortality rate per reason for mortality. COVID-19, coronavirus disease 2019. ∗Arrows in this figure indicate the date when the respective medical product was made available for the very first time in the world. This is applicable to some of the contributing institutions, not to them all.